The evaluation of cyclin D1 expression in prostate carcinoma cases.

OBJECTIVE

Cyclin D1 (CDDN1) is an important protein for mitotic cell cycle advancement through the G1 phase and contributes to the control of the cyclin-dependent kinases CDK4 and CDK6. We evaluated the relationship between CDDN1 expression and clinicopathological features in prostate cancer (PCa) cases and whether CDDN1 could be used as a prognostic biomarker for PCa cases in this study.

METHODS

This study comprised ninety cases; seventy-five had PCa and fifteen had benign prostatic hypertrophy (BPH) diagnoses (as the control group). The pathological specimens were stained immunohistochemically and categorized as a 'low' (L) or a 'high' (H) group for CDDN1 expression. The cases' clinicopathological features and survival rates were evaluated statistically, within a 95% confidence interval, p<0.05, retrospectively.

RESULTS

The median follow-up time was 75 (17-96) months, and the median overall survival (OS) was 87 months (CI 95%: 74.74-99.25). While the OS was 66 months (CI 95%: 49.61-82.38) in the H-CDDN1 group, the OS of the L-CDDN1 group was not yet reached. The OS of the L-CDDN1 group was longer in statistical significance (p=0.011). A Cox regression analysis revealed that the levels of CDDN1 expression, the values of lactate dehydrogenase, and post-treatment prostate specific antigen were found to be prognostic factors for OS in PCa cases (p<0.05).

CONCLUSION

Our results suggest the overexpression of CDDN1 is a potentially useful but poor prognostic biomarker for PCa cases.